Jump to main content
Jump to site search

Issue 4, 2012
Previous Article Next Article

The MEP pathway and the development of inhibitors as potential anti-infective agents

Author affiliations

Abstract

The non-mevalonate (or MEP) pathway represents an essential biosynthetic route used by plants, algae, and eubacteria to generate isoprenoid precursors. The MEP pathway has also been genetically validated in pathogenic organisms such as P. falciparum and M. tuberculosis. As this pathway is absent in mammalian systems, the enzymes of the MEP pathway represent attractive targets for the development of novel herbicides and antimicrobial chemotherapeutics. This review examines the enzymes in the MEP pathway from a detailed medicinal chemistry and structural biology perspective. The binding modes of substrates and inhibitors are discussed, identifying key interactions that maybe exploitable in small molecule inhibitor design.

Graphical abstract: The MEP pathway and the development of inhibitors as potential anti-infective agents

Back to tab navigation

Supplementary files

Publication details

The article was received on 05 Dec 2011, accepted on 20 Jan 2012 and first published on 23 Jan 2012


Article type: Review Article
DOI: 10.1039/C2MD00298A
Citation: Med. Chem. Commun., 2012,3, 418-433
  •   Request permissions

    The MEP pathway and the development of inhibitors as potential anti-infective agents

    I. Hale, P. M. O'Neill, N. G. Berry, A. Odom and R. Sharma, Med. Chem. Commun., 2012, 3, 418
    DOI: 10.1039/C2MD00298A

Search articles by author

Spotlight

Advertisements